Nuveen LLC Takes Position in CVRx, Inc. $CVRX

Key Points

• Nuveen LLC acquired a new stake in CVRx, Inc., purchasing 42,289 shares valued at approximately $517,000, representing 0.16% of the company.
• The firm's stock opened at $7.70 with a market cap of $201.36 million, experiencing significant fluctuations over the past year, with a low of $4.30 and a high of $18.55.
• Analysts have mixed views on CVRx, with Piper Sandler lowering their price target from $20.00 to $12.00, while William Blair upgraded the stock to a "strong-buy" rating.

Nuveen LLC bought a new stake in CVRx, Inc. (NASDAQ:CVRX - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 42,289 shares of the company's stock, valued at approximately $517,000. Nuveen LLC owned approximately 0.16% of CVRx at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Wells Fargo & Company MN lifted its position in CVRx by 86.1% in the fourth quarter. Wells Fargo & Company MN now owns 8,894 shares of the company's stock valued at $113,000 after acquiring an additional 4,115 shares during the last quarter. Barclays PLC increased its position in shares of CVRx by 12.1% during the fourth quarter. Barclays PLC now owns 21,378 shares of the company's stock worth $270,000 after purchasing an additional 2,311 shares in the last quarter. MetLife Investment Management LLC purchased a new stake in shares of CVRx in the 4th quarter valued at about $111,000. Tower Research Capital LLC TRC boosted its position in shares of CVRx by 43.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,900 shares of the company's stock valued at $49,000 after purchasing an additional 1,186 shares during the period. Finally, Northern Trust Corp grew its stake in CVRx by 4.3% during the 4th quarter. Northern Trust Corp now owns 138,883 shares of the company's stock worth $1,760,000 after buying an additional 5,671 shares during the last quarter. 75.27% of the stock is owned by hedge funds and other institutional investors.

CVRx Stock Performance

Shares of NASDAQ:CVRX traded down $0.18 during trading on Wednesday, reaching $7.88. The company had a trading volume of 127,759 shares, compared to its average volume of 184,462. CVRx, Inc. has a fifty-two week low of $4.30 and a fifty-two week high of $18.55. The company has a debt-to-equity ratio of 0.85, a current ratio of 11.99 and a quick ratio of 10.78. The stock's fifty day moving average price is $7.58 and its 200 day moving average price is $8.07. The firm has a market capitalization of $206.06 million, a price-to-earnings ratio of -3.75 and a beta of 1.26.

CVRx (NASDAQ:CVRX - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.52) by ($0.05). The firm had revenue of $13.59 million during the quarter, compared to analysts' expectations of $13.22 million. CVRx had a negative net margin of 95.61% and a negative return on equity of 79.31%. CVRx has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, equities research analysts predict that CVRx, Inc. will post -1.91 EPS for the current year.

Analyst Ratings Changes

CVRX has been the subject of a number of research reports. Cantor Fitzgerald reiterated an "overweight" rating and issued a $11.00 price objective on shares of CVRx in a research note on Tuesday, August 5th. William Blair raised shares of CVRx to a "strong-buy" rating in a report on Monday, July 7th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, CVRx currently has an average rating of "Moderate Buy" and an average target price of $14.00.

CVRx Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.